U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H13NO3S2
Molecular Weight 319.399
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of EPALRESTAT

SMILES

CC(=C/C1=CC=CC=C1)\C=C2/SC(=S)N(CC(O)=O)C2=O

InChI

InChIKey=CHNUOJQWGUIOLD-NFZZJPOKSA-N
InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-

HIDE SMILES / InChI
Molecular Formula C15H13NO3S2
Molecular Weight 319.399
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 2
Optical Activity NONE

Description

Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy.

CNS Activity

CNS Penetrant
2,554

Originator

Ono Pharmaceutical
18

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
Aldose reductase
44
Inhibitor
8,297
 0.28 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diabetic neuropathy
23
 Primary
Approved
8,429
KINEDAK

Cmax

ValueDoseCo-administeredAnalytePopulation
3.9 μg/mL
50 mg single, oral
 EPALRESTAT plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
6.4 μg × h/mL
50 mg single, oral
 EPALRESTAT plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
9.9%
50 mg single, oral
 EPALRESTAT plasma
Homo sapiens

Doses

AEs

PubMed

Patents

JP2001163805A
2
JP2002536332A
38
JP2004051520A
2
JP2004210702A
2
JP2004210703A
2
JP2004210766A
2
JP2004210775A
2
JP2005139085A
3
JP2005139086A
3
JP2005298424A
2
JP2006104064A
2
JP2006111601A
2
JP2006282526A
2
JP2006528156A
10
JP2007099680A
2
JP2007505083A
6
JP2007505085A
6
JP2009029717A
2
JP2011507800A
48
JP5294046B2
2

Sample Use Guides

In Vivo Use Guide
50 mg, 3 times/day
Route of Administration: Oral
In Vitro Use Guide
Human umbilical vein endothelial cells were cultured for 48 h in glucose-rich (27.8 mM) medium. The increased neutrophil-endothelial cell adhesion and surface expression of intercellular adhesion molecule-1 (ICAM-1), P-selectin, and E-selectin on endothelial cells was inhibited by 10 microM of epalrestat.
Substance Class Chemical
Record UNII
424DV0807X
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966